Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
The European Commission has approved ENFLONSIA (clesrovimab) as the first RSV preventive option for infants in the EU.
Asset / Drug
Drug and asset intelligence for ENFLONSIA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.